Following on from the news that Lutetium (177lu) oxodotreotide was recommended, today we can share with you the Final Appraisal Document for Lutetium (177lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease.
[npfButton size=“small” text=”Find out more” href=”https://www.nice.org.uk/guidance/ta539″ background-colour=”#37b8c0″ text-colour=”#ffffff”]
The UK and the Republic of Ireland run the only formal national programme for liver transplantation in patients with neuroendocrine tumours, and evidence shows those transplanted ...
Ongoing variability in the supply of pancreatic enzyme replacement therapy (PERT) — particularly Creon® 25,000iu capsules — has left some people struggling to obtain their prescription. ...